跳至主要内容
临床试验/NCT00331058
NCT00331058终止1 期

A Study To Validate Key Therapeutic Targets and Characterise Their Response to Corticosteroids in Multiple Asthma Phenotypes

GlaxoSmithKline3 个研究点 分布在 1 个国家目标入组 58 人开始时间: 2006年2月18日最近更新:
适应症

试验速览

阶段
1 期
状态
终止
入组人数
58
试验地点
3
主要终点
evaluate changes in target expression in response to a 2 week course of corticosteroids across the 4 asthma phenotypes

研究概览

简要总结

The primary goal of this study is to compare the expression of key GSK drug targets across the 4 asthma phenotypes and healthy subjects and secondarily to evaluate changes in target expression in response to a 2-week course of corticosteroids across the 4 asthma phenotypes. Each asthmatic subject in this study will undergo two bronchoscopies. Each healthy subject will undergo one bronchoscopy.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Basic Science
盲法
None

入排标准

年龄范围
18 Years 至 45 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

evaluate changes in target expression in response to a 2 week course of corticosteroids across the 4 asthma phenotypes

时间窗: visits 3 through to and including visit 6

compare key drug targets across 4 asthma phenotypes and healthy subjects

时间窗: visits 3 through to and including visit 6

次要结局

  • Cytospins(visits 3 through to and including visit 6)
  • Histopathology on bronchial biopsies(visits 3 through to and including visit 6)
  • target expression in the blood(visits 3 through to and including visit 6)
  • inflammatory markers(visits 3 through to and including visit 6)
  • Quality of life (QoL) and symptom scores(visits 3 through to and including visit 6)
  • activation state of a signalling pathway(visits 3 through to and including visit 6)
  • target protein expression(visits 3 through to and including visit 6)
  • Measures of pulmonary inflammation(visits 3 through to and including visit 6)
  • Assessments of lung structure(visits 3 through to and including visit 6)
  • lung function(visits 3 through to and including visit 6)
  • Changes in medication(visits 3 through to and including visit 6)
  • new targets and biomarkers(visits 3 through to and including visit 6)
  • Radiological Parameters(visits 3 through to and including visit 6)
  • Pharmacogenomics from blood samples(visits 3 through to and including visit 6)
  • Whole Blood TaqMan and/or transcriptomic analysis(visits 3 through to and including visit 6)
  • TaqMan and/or Differential Gene Expression and Proteomics(visits 3 through to and including visit 6)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (3)

Loading locations...

相似试验